Vanda Pharmaceuticals Inc. (VNDA)
NASDAQ: VNDA · Real-Time Price · USD
4.935
-0.155 (-3.05%)
Aug 6, 2026, 10:45 AM EDT - Market open
Vanda Pharmaceuticals Market Cap
Vanda Pharmaceuticals has a market cap or net worth of $296.77 million as of August 6, 2026. Its market cap has increased by 19.86% in one year.
Market Cap
296.77M
Enterprise Value
154.26M
1-Year Change
19.86%
Ranking
Category
Stock Price
$4.94
ChartMarket Cap Chart
Since April 12, 2006, Vanda Pharmaceuticals's market cap has increased from $209.50M to $296.77M, an increase of 41.66%. That is a compound annual growth rate of 1.73%.
| Date | Market Cap | % Change |
|---|---|---|
| Aug 4, 2026 | 320.50M | -38.51% |
| Dec 31, 2025 | 521.20M | 86.61% |
| Dec 31, 2024 | 279.30M | 15.03% |
| Dec 29, 2023 | 242.80M | -41.94% |
| Dec 30, 2022 | 418.20M | -52.16% |
| Dec 31, 2021 | 874.10M | 21.64% |
| Dec 31, 2020 | 718.60M | -17.90% |
| Dec 31, 2019 | 875.30M | -36.13% |
| Dec 31, 2018 | 1.37B | 100.69% |
| Dec 29, 2017 | 682.90M | -2.57% |
| Dec 30, 2016 | 700.90M | 75.84% |
| Dec 31, 2015 | 398.60M | -17.90% |
| Dec 31, 2014 | 485.50M | 17.87% |
| Dec 31, 2013 | 411.90M | 294.54% |
| Dec 31, 2012 | 104.40M | -21.97% |
| Dec 30, 2011 | 133.80M | -49.57% |
| Dec 31, 2010 | 265.30M | -13.30% |
| Dec 31, 2009 | 306.00M | 2,200.75% |
| Dec 31, 2008 | 13.30M | -92.75% |
| Dec 31, 2007 | 183.40M | -66.04% |
| Dec 29, 2006 | 540.00M | 157.76% |
| Apr 12, 2006 | 209.50M | - |
View and export this data all the way back to 2006. Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Opus Genetics | 312.92M |
| Fate Therapeutics | 301.31M |
| Neumora Therapeutics | 298.31M |
| OmniAb | 295.74M |
| Anavex Life Sciences | 295.62M |
| Sol-Gel Technologies | 288.98M |
| Fulcrum Therapeutics | 287.26M |
| Foghorn Therapeutics | 286.52M |